Kestra Private Wealth Services LLC Sells 326 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Kestra Private Wealth Services LLC decreased its position in Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating) by 29.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 784 shares of the medical research company’s stock after selling 326 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Bio-Rad Laboratories were worth $442,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. State Board of Administration of Florida Retirement System boosted its holdings in Bio-Rad Laboratories by 1.9% during the first quarter. State Board of Administration of Florida Retirement System now owns 23,117 shares of the medical research company’s stock worth $13,020,000 after purchasing an additional 441 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Bio-Rad Laboratories by 0.7% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 67,331 shares of the medical research company’s stock valued at $37,923,000 after acquiring an additional 452 shares during the last quarter. HighTower Advisors LLC raised its holdings in Bio-Rad Laboratories by 1.2% during the first quarter. HighTower Advisors LLC now owns 7,184 shares of the medical research company’s stock worth $4,054,000 after acquiring an additional 86 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund boosted its position in Bio-Rad Laboratories by 11.3% during the first quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 638 shares of the medical research company’s stock valued at $359,000 after purchasing an additional 65 shares during the last quarter. Finally, Stephens Inc. AR grew its stake in Bio-Rad Laboratories by 16.5% in the first quarter. Stephens Inc. AR now owns 566 shares of the medical research company’s stock valued at $319,000 after purchasing an additional 80 shares in the last quarter. 64.33% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Trading Down 0.7 %

BIO stock opened at $445.50 on Tuesday. Bio-Rad Laboratories, Inc. has a one year low of $437.13 and a one year high of $804.65. The stock has a market cap of $13.23 billion, a price-to-earnings ratio of -6.72 and a beta of 0.99. The company has a fifty day moving average price of $510.35 and a two-hundred day moving average price of $522.60. The company has a debt-to-equity ratio of 0.13, a current ratio of 5.30 and a quick ratio of 4.22.

Bio-Rad Laboratories (NYSE:BIOGet Rating) last announced its earnings results on Thursday, July 28th. The medical research company reported $3.38 EPS for the quarter, topping the consensus estimate of $2.46 by $0.92. The business had revenue of $691.10 million during the quarter, compared to the consensus estimate of $664.60 million. Bio-Rad Laboratories had a negative net margin of 67.66% and a positive return on equity of 3.82%. Bio-Rad Laboratories’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.54 EPS. Equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 14.35 EPS for the current year.

Wall Street Analyst Weigh In

BIO has been the subject of several analyst reports. Credit Suisse Group initiated coverage on shares of Bio-Rad Laboratories in a research note on Wednesday, August 24th. They issued an “outperform” rating and a $715.00 target price for the company. Citigroup lowered their price objective on shares of Bio-Rad Laboratories from $750.00 to $700.00 and set a “buy” rating on the stock in a research note on Friday, July 8th. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $705.00.

Insider Transactions at Bio-Rad Laboratories

In related news, CAO Ajit Ramalingam sold 518 shares of the business’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of $537.00, for a total value of $278,166.00. Following the completion of the sale, the chief accounting officer now directly owns 98 shares in the company, valued at approximately $52,626. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 27.40% of the stock is owned by corporate insiders.

About Bio-Rad Laboratories

(Get Rating)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Featured Articles

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.